Latest filing published 12 Aug 2026 for Replimune Group, Inc., €442k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Filings by Sushil Patel span 2 companies, the busiest being Replimune Group, Inc. and Revolution Medicines, Inc. Over a trading history stretching from 3 May 2021 to 10 August 2026, the count stands at 23 filings.
Sales make up the whole of the open-market record (8 sales, €1.5M). Besides market trades, the filings include 12 share grants and 3 option exercises. So far in 2026, the count stands at no purchases and 1 sale.
Most recently, on 12 August 2026, the filings show an open-market sale worth €442k in Replimune Group, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
23 of 23 declarations